INTRODUCTION

The rupture of vulnerable plaques in the coronary arteries mainly triggers acute coronary syndromes, such as unstable angina and acute myocardial infarction. Coronary artery spasm is also important in the occurrence of cardiovascular events including acute coronary syndromes. We recently demonstrated that Rho-kinase is a novel therapeutic target for the treatment of cardiovascular diseases such as coronary vasospasm. The Rho-kinase inhibitor, fasudil, suppresses coronary artery spasm in patients with vasospastic angina, but the potential for the treatment of acute coronary syndromes remains to be examined. Here we report a patient with unstable angina pectoris in whom fasudil was effective for controlling anginal attacks.

CASE REPORT

An 86-year-old woman was admitted with unstable angina pectoris. Plain old balloon angioplasty (POBA) was performed for 90% stenosis at segment 7 of the left coronary artery with concomitant treatment with nitrate, calcium antagonists, and nicorandil. Five days after POBA, she again suffered chest pain at rest with ST depression by electrocardiography, despite increased doses of calcium-antagonist and nicorandil. Coronary arteriography showed no evidence of restenosis at the POBA site. The involvement of coronary artery spasm was considered and intravenous treatment with a Rho-kinase inhibitor, fasudil, was started, which resulted in disappearance of the anginal attacks. She refused to continue the fasudil treatment on day 5, which resulted in reappearance of anginal attacks. Third coronary angiography showed a 90% restenosis at POBA site and percutaneous coronary intervention was again performed. This case suggests that a Rho-kinase inhibitor is potentially effective to prevent anginal attacks in spastic angina.

Key Words

Unstable angina (spastic)  Vasodilator agents (Rho-kinase inhibitor)
abnormal ST-T changes. Mild exercise test induced an ischemic ST-segment depression with a negative U wave in leads $\bar{3} - \bar{5}$. Echocardiography revealed no left ventricular wall motion abnormality, mild aortic regurgitation, and minimal mitral regurgitation. During the first week after admission, she repeatedly suffered from chest pain either on exertion or at rest, which worsened day by day.

Antianginal treatment was started with isosorbide dinitrate (20 mg/day), diltiazem hydrochloride (120 mg/day) and metoprolol (60 mg/day; Fig. 1). Coronary angiography showed a 90% stenosis at segment 7 of the left coronary artery (Fig. 2-A). Plain old balloon angioplasty (POBA) of the stenotic segment was performed which reduced the stenosis to 25% (Fig. 2-B). Five days after the process.

**Fig. 1** In-hospital course of a patient with unstable angina, showing chest symptoms, antianginal medical treatment, and coronary intervention
CAG = coronary angiography; POBA = plain old balloon angioplasty.

**Fig. 2** Coronary angiograms of a patient with unstable angina
A: Left CAG on admission showing the culprit lesion in segment (arrow)
B: CAG after plain old balloon angioplasty showing a 25% stenosis in segment (arrow)
C: Second left CAG showing a 50% restenosis in segment (arrow)
D: Third left CAG showing a 90% restenosis in segment (arrow)
E: CAG after stenting to segment 7 showing resolution of the stenosis (arrow) after stenting.
PCI = percutaneous coronary intervention. Other abbreviation as in Fig. 1.
POBA site angiography showed no significant stenosis at the POBA site (50% restenosis; Fig. 2). We did not choose re-POBA at this time, because we considered that coronary artery spasm was the major reason for the anginal attacks at rest. Even after increasing the dose of diltiazem hydrochloride to 180 mg, decreasing the dose of metoprolol to 30 mg, and adding 20 mg of nicorandil, she continued to complain of chest pain at rest.

Intravenous treatment with the Rho-kinase inhibitor fasudil (30 mg, three times every 8 hr) was then started. During the treatment with fasudil, no anginal attacks were noted (Fig. 1). However, the fasudil treatment was discontinued on day 5, because she did not like continuous intravenous administration. Three days later, she again had chest pain. Third coronary angiography showed a 90% restenotic lesion at the POBA site (Fig. 2). Coronary stenting was performed at the lesion (Fig. 2). After this procedure, no anginal attacks were noted.

**DISCUSSION**

The administration of the Rho-kinase inhibitor fasudil was effective in controlling anginal attacks in the present patient with spastic angina, although we have no evidence that fasudil directly relieved coronary vasospasm in this patient. Rho-kinase is substantially involved in the molecular mechanisms of coronary artery spasm and fasudil suppresses the spasm in both humans and animals. Rho-kinase inhibits myosin phosphatase activity by phosphorylating the myosin-binding subunit of the enzyme and thus augments vascular smooth muscle contraction at a given calcium concentration. Increased calcium sensitization of vascular smooth muscle cells mediated by the activated Rho-kinase pathway is very important in coronary artery spasm. Fasudil hydrochloride is the only inhibitor of Rho-kinase that can be applied to humans. It has a reasonable inhibitory effect on Rho-kinase, 10 times and 100 times more potent than on protein kinase C and myosin light chain kinase, respectively. Importantly, fasudil attenuates only abnormally hypercontractile responses of spastic coronary arteries and does not affect those of normal coronary arteries. Rho-kinase inhibition suppresses cell migration and may have potential adverse effects on atherosclerotic progression, although the present patient showed restenosis at the POBA site. The present case suggests that Rho-kinase is a new class of vasodilator for the treatment of spastic angina.
References